Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa

First subject dosed in Phase I study to evaluate safety and tolerability of…


Infex Awarded Biomedical Catalyst Grant For COV-X Project

Alderley Park, Cheshire, U.K - Infex Therapeutics, a leading anti-infectives…


COVID-19 Pandemic Triggers Upsurge in MBL Infections

New research has discovered that the ongoing COVID-19 pandemic has triggered a…


CARB-X Receives Additional $370m from U.S. Government and Wellcome

Enables continued investment in innovative projects to tackle the growing…


Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism

Alderley Park, Cheshire - Infex Therapeutics, one of the UK’s leading…


Infex scientists achieve breakthrough to overcome critical priority drug resistant infections

Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…


Infex agrees partnership with Colibri Scientific to provide services for RESP-X program

Alderley Park, Cheshire Infex Therapeutics has today announced a deal with…


Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains

Alderley Park, Cheshire –  One of the UK’s leading infectious disease biotech…


Tackling underlying respiratory conditions for this pandemic and next

During the COVID-19 pandemic, one of the many phrases that has become…